Absolute lymphocyte count: A potential prognostic factor for Merkel cell carcinoma - 14/05/14
Abstract |
Background |
Absolute lymphocyte count (ALC) is a laboratory value commonly obtained during workup of patients with Merkel cell carcinoma (MCC).
Objective |
We report the prognostic impact of ALC as a surrogate of immune status in MCC.
Methods |
A complete blood cell count was available for 64 patients with MCC in the month before definitive surgery, chemotherapy, or radiation. Statistical analysis was performed with classification and regression tree analysis, log rank test, and Cox model.
Results |
Median overall survival (OS) for the cohort was 97 months. Median OS for patients with an ALC less than 1.1 k/mm3 was 18.8 versus 110.1 months for those with ALC greater than or equal to 1.1 k/mm3 (P = .002, hazard ratio 0.29). Multivariate analysis of OS controlling for ALC, sex, stage, adjuvant chemotherapy, hematologic malignancy, and immunosuppression demonstrated ALC as a prognostic factor (P = .03). Disease-free survival at 36 months for ALC less than 1.1 k/mm3 was 26.9% versus 64.4% for those with ALC greater than or equal to 1.1 k/mm3 (P = .01). ALC was not a significant predictor for disease-free survival on multivariate analysis (P = .12).
Limitations |
This is a single-institution retrospective data set.
Conclusion |
ALC is associated with OS but not disease-free survival in MCC using a threshold of less than 1.1 k/mm3. This test may provide additional prognostic information for patients with MCC.
Le texte complet de cet article est disponible en PDF.Key words : absolute lymphocyte count, immune function, Merkel cell carcinoma, skin cancer, skin neoplasm
Abbreviations used : AJCC, ALC, CART, CBC, CI, DFS, FCCC, HR, MCC, MCV, OS
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 70 - N° 6
P. 1028-1035 - juin 2014 Retour au numéro
Article précédent
- Histiocytoid Sweet syndrome may indicate leukemia cutis: A novel application of fluorescence in situ hybridization
- Rahul N. Chavan, Mark A. Cappel, Rhett P. Ketterling, David A. Wada, Nicole M. Rochet, Ryan Knudson, Lawrence E. Gibson
- Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma
- Sara Harcharik, Sebastian Bernardo, Marina Moskalenko, Michael Pan, Meera Sivendran, Heather Bell, Lawrence D. Hall, Mireia Castillo-Martín, Kelly Fox, Carlos Cordon-Cardo, Rui Chang, Shanthi Sivendran, Robert G. Phelps, Yvonne Saenger
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?